Allan Steven Jacobson Sells 14,199 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson sold 14,199 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $83.55, for a total value of $1,186,326.45. Following the completion of the sale, the director directly owned 17,451 shares in the company, valued at approximately $1,458,031.05. This represents a 44.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Allan Steven Jacobson also recently made the following trade(s):

• On Monday, November 24th, Allan Steven Jacobson sold 11,801 shares of PTC Therapeutics stock. The stock was sold at an average price of $80.14, for a total transaction of $945,732.14.
• On Friday, October 3rd, Allan Steven Jacobson sold 12,000 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.00, for a total transaction of $780,000.00.
• On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The shares were sold at an average price of $50.15, for a total transaction of $83,600.05.
• On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.15, for a total transaction of $83,600.05.

PTC Therapeutics Stock Up 4.0%

NASDAQ:PTCT opened at $86.25 on Friday. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of 12.37 and a beta of 0.60. The company’s 50 day moving average price is $68.89 and its 200-day moving average price is $56.65. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The business had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. During the same period in the prior year, the firm posted ($1.39) EPS. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on PTCT. Jefferies Financial Group raised their target price on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research note on Tuesday. Royal Bank Of Canada boosted their target price on shares of PTC Therapeutics from $70.00 to $82.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Finally, Wells Fargo & Company increased their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $75.40.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC boosted its holdings in shares of PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. boosted its stake in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares during the period. Comerica Bank boosted its stake in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the period. Quantbot Technologies LP boosted its position in shares of PTC Therapeutics by 545.5% during the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 551 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 320 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.